KINIKSA PHARMACEUTICALS INTE (KNSA) Fundamental Analysis & Valuation

NASDAQ:KNSA • GB00BRXB0C07

Current stock price

47.33 USD
+0.3 (+0.64%)
At close:
47.33 USD
0 (0%)
After Hours:

This KNSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. KNSA Profitability Analysis

1.1 Basic Checks

  • In the past year KNSA was profitable.
  • KNSA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
  • KNSA had a positive operating cash flow in 4 of the past 5 years.
KNSA Yearly Net Income VS EBIT VS OCF VS FCFKNSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • With an excellent Return On Assets value of 7.73%, KNSA belongs to the best of the industry, outperforming 92.65% of the companies in the same industry.
  • The Return On Equity of KNSA (10.40%) is better than 92.65% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.21%, KNSA belongs to the top of the industry, outperforming 92.07% of the companies in the same industry.
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROIC 8.21%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
KNSA Yearly ROA, ROE, ROICKNSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.71%, KNSA belongs to the top of the industry, outperforming 90.52% of the companies in the same industry.
  • In the last couple of years the Profit Margin of KNSA has declined.
  • KNSA has a better Operating Margin (11.40%) than 91.10% of its industry peers.
  • KNSA's Operating Margin has improved in the last couple of years.
  • The Gross Margin of KNSA (88.54%) is better than 90.33% of its industry peers.
  • KNSA's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
KNSA Yearly Profit, Operating, Gross MarginsKNSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. KNSA Health Analysis

2.1 Basic Checks

  • KNSA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • KNSA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, KNSA has more shares outstanding
  • There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KNSA Yearly Shares OutstandingKNSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
KNSA Yearly Total Debt VS Total AssetsKNSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • KNSA has an Altman-Z score of 12.07. This indicates that KNSA is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.07, KNSA belongs to the top of the industry, outperforming 83.17% of the companies in the same industry.
  • There is no outstanding debt for KNSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.07
ROIC/WACC0.88
WACC9.33%
KNSA Yearly LT Debt VS Equity VS FCFKNSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • KNSA has a Current Ratio of 3.79. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
  • KNSA has a Current ratio (3.79) which is comparable to the rest of the industry.
  • KNSA has a Quick Ratio of 3.39. This indicates that KNSA is financially healthy and has no problem in meeting its short term obligations.
  • KNSA has a Quick ratio (3.39) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.39
KNSA Yearly Current Assets VS Current LiabilitesKNSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. KNSA Growth Analysis

3.1 Past

  • KNSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 221.31%, which is quite impressive.
  • Measured over the past years, KNSA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -34.14% on average per year.
  • The Revenue has grown by 60.09% in the past year. This is a very strong growth!
  • Measured over the past years, KNSA shows a very strong growth in Revenue. The Revenue has been growing by 45.45% on average per year.
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%

3.2 Future

  • Based on estimates for the next years, KNSA will show a very strong growth in Earnings Per Share. The EPS will grow by 45.16% on average per year.
  • The Revenue is expected to grow by 17.42% on average over the next years. This is quite good.
EPS Next Y105.97%
EPS Next 2Y76.67%
EPS Next 3Y48.01%
EPS Next 5Y45.16%
Revenue Next Year35.13%
Revenue Next 2Y26.15%
Revenue Next 3Y22.39%
Revenue Next 5Y17.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KNSA Yearly Revenue VS EstimatesKNSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
KNSA Yearly EPS VS EstimatesKNSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

6

4. KNSA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 63.96, KNSA can be considered very expensive at the moment.
  • 89.94% of the companies in the same industry are more expensive than KNSA, based on the Price/Earnings ratio.
  • KNSA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.91.
  • With a Price/Forward Earnings ratio of 31.05, KNSA can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, KNSA is valued cheaply inside the industry as 92.07% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of KNSA to the average of the S&P500 Index (23.68), we can say KNSA is valued slightly more expensively.
Industry RankSector Rank
PE 63.96
Fwd PE 31.05
KNSA Price Earnings VS Forward Price EarningsKNSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 91.30% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 94.20% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 26.56
EV/EBITDA 37.58
KNSA Per share dataKNSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • KNSA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of KNSA may justify a higher PE ratio.
  • A more expensive valuation may be justified as KNSA's earnings are expected to grow with 48.01% in the coming years.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y76.67%
EPS Next 3Y48.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KNSA Dividend Analysis

5.1 Amount

  • No dividends for KNSA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KNSA Fundamentals: All Metrics, Ratios and Statistics

KINIKSA PHARMACEUTICALS INTE

NASDAQ:KNSA (4/9/2026, 8:00:03 PM)

After market: 47.33 0 (0%)

47.33

+0.3 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)04-21
Inst Owners95.47%
Inst Owner Change0%
Ins Owners3.24%
Ins Owner Change-18.77%
Market Cap3.62B
Revenue(TTM)677.56M
Net Income(TTM)59.01M
Analysts85.71
Price Target56.97 (20.37%)
Short Float %8.52%
Short Ratio5.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-42.87%
Min EPS beat(2)-55.48%
Max EPS beat(2)-30.25%
EPS beat(4)2
Avg EPS beat(4)23.7%
Min EPS beat(4)-55.48%
Max EPS beat(4)156.77%
EPS beat(8)3
Avg EPS beat(8)-795.94%
EPS beat(12)6
Avg EPS beat(12)-483.47%
EPS beat(16)10
Avg EPS beat(16)-333.06%
Revenue beat(2)2
Avg Revenue beat(2)3.78%
Min Revenue beat(2)1.62%
Max Revenue beat(2)5.94%
Revenue beat(4)4
Avg Revenue beat(4)4.02%
Min Revenue beat(4)1.62%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)2.71%
Revenue beat(12)9
Avg Revenue beat(12)6.1%
Revenue beat(16)12
Avg Revenue beat(16)8.92%
PT rev (1m)-0.03%
PT rev (3m)2.09%
EPS NQ rev (1m)-29.82%
EPS NQ rev (3m)-36.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.42%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)1.37%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)4.26%
Valuation
Industry RankSector Rank
PE 63.96
Fwd PE 31.05
P/S 5.35
P/FCF 26.56
P/OCF 26.25
P/B 6.38
P/tB 6.56
EV/EBITDA 37.58
EPS(TTM)0.74
EY1.56%
EPS(NY)1.52
Fwd EY3.22%
FCF(TTM)1.78
FCFY3.77%
OCF(TTM)1.8
OCFY3.81%
SpS8.85
BVpS7.42
TBVpS7.22
PEG (NY)0.6
PEG (5Y)N/A
Graham Number11.11
Profitability
Industry RankSector Rank
ROA 7.73%
ROE 10.4%
ROCE 12.37%
ROIC 8.21%
ROICexc 24.37%
ROICexgc 26.28%
OM 11.4%
PM (TTM) 8.71%
GM 88.54%
FCFM 20.13%
ROA(3y)0.99%
ROA(5y)-5%
ROE(3y)1.25%
ROE(5y)-7.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y102.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y102.78%
ROICexc growth 5YN/A
OM growth 3Y36.93%
OM growth 5YN/A
PM growth 3Y-52.89%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5YN/A
F-Score8
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 100.9%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 175.16%
Profit Quality 231.2%
Current Ratio 3.79
Quick Ratio 3.39
Altman-Z 12.07
F-Score8
WACC9.33%
ROIC/WACC0.88
Cap/Depr(3y)40.93%
Cap/Depr(5y)198.53%
Cap/Sales(3y)0.11%
Cap/Sales(5y)10.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)221.31%
EPS 3Y-34.14%
EPS 5YN/A
EPS Q2Q%241.67%
EPS Next Y105.97%
EPS Next 2Y76.67%
EPS Next 3Y48.01%
EPS Next 5Y45.16%
Revenue 1Y (TTM)60.09%
Revenue growth 3Y45.45%
Revenue growth 5YN/A
Sales Q2Q%64.95%
Revenue Next Year35.13%
Revenue Next 2Y26.15%
Revenue Next 3Y22.39%
Revenue Next 5Y17.42%
EBIT growth 1Y269.29%
EBIT growth 3Y99.18%
EBIT growth 5YN/A
EBIT Next Year113.76%
EBIT Next 3Y67.22%
EBIT Next 5YN/A
FCF growth 1Y436.82%
FCF growth 3Y188.18%
FCF growth 5YN/A
OCF growth 1Y437.14%
OCF growth 3Y187.44%
OCF growth 5YN/A

KINIKSA PHARMACEUTICALS INTE / KNSA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?

ChartMill assigns a fundamental rating of 7 / 10 to KNSA.


What is the valuation status of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

ChartMill assigns a valuation rating of 6 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Fairly Valued.


What is the profitability of KNSA stock?

KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 7 / 10.


What is the expected EPS growth for KINIKSA PHARMACEUTICALS INTE (KNSA) stock?

The Earnings per Share (EPS) of KINIKSA PHARMACEUTICALS INTE (KNSA) is expected to grow by 105.97% in the next year.